Microbiota and Bone Fragility:Study of the Relation Between Gut Microbiota and Bone Microarchitecture

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

440 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-08

Study Completion Date

2022-02-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gut microbiota regulate metabolism of their human host. Some diseases are associated with variations in gut microbiota diversity and higher fracture risk. Intestinal bacteria synthesize or influence synthesis of factors modulating bone metabolism. The link between gut microbiota and bone was assessed mainly in experimental animal studies. Clinical data, e.g. on the role of gut microbiota in postmenopausal osteoporosis are scarce. The investigators will compare gut microbiota composition in four groups of women aged ≥60 recruited on the basis of bone mineral density (BMD) and personal history of fracture. the participants will have diagnostic exams: clinical tests, bone densitometry (body composition, vertebral fractures), high resolution peripheral QCT (bone strength estimated by microfinite element analysis, micro-FEA), biological sample collection. Gut microbiome profiling will be performed at the INRA MetaGenoPolis laboratory. The investigators will compare gut microbiota diversity according to BMD level and to the fracture status. The investigators will analyze interactions of the gut microbiota diversity with bone status (bone turnover rate, BMD, bone microarchitecture, bone strength estimated by micro-FEA), muscle mass and strength, inflammatory cytokines and micro-RNAs modulating their expression. This study will provide new data concerning the importance of gut microbiota for the fracture risk in older women. It will help to identify the main metabolic pathways underlying the observed associations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiological Biological Genetic and Micro-architectural Bone Determinants of Fractures in Men With Low Bone Mineral Density

NCT01250314

Osteoporosis

COMPLETED NA

Mother Daughter Bone Microarchitecture

NCT01258036

Bone Fragility

COMPLETED

The Oswestry Metabolic BONE Cohort

NCT07014306

Osteoporosis

NOT_YET_RECRUITING

Linking Dietary Nutrition, Dietary Patterns, Gut Microbiota, and Bone Density: A Cross-Sectional Study

NCT07256314

Bone Density Gut Microbiomes

COMPLETED

Multicenter Cohort Study on Osteoporosis

NCT02958020

Osteoporosis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Postmenopausal osteoporosis is a major public health problem in developed countries. Despite the progress, knowledge of its pathophysiological mechanisms and identification of women at high risk of fracture in the clinical practice are not satisfactory. Gut microbiota consist of trillions of commensal bacteria playing a major role in the regulation of metabolism of their human host. Some conditions (diabetes mellitus, obesity, liver cirrhosis, inflammatory bowel disease, end stage renal disease, depression, heavy drinking, heavy smoking) are associated with variations in gut microbiota diversity and higher risk of fracture. Intestinal bacteria synthesize or influence the synthesis of factors which modulate bone metabolism, e.g. lipopolysaccharide (present in the wall of Gram-negative bacteria), inflammatory cytokines (synthesized in the gut associated lymphoid tissue), serotonin (synthesized in the colon epithelium), short-chain fatty acids, estrogens (deconjugation of sulphates and glucuronides). Data on the association between gut microbiota and bone metabolism were obtained mainly in experimental animal studies. Clinical data are limited. Data on the possible role of gut microbiota in the pathophysiology of the postmenopausal osteoporosis are scarce.

The investigators will carry out a cross-sectional comparison of gut microbiota composition in four groups of women aged 60 and over recruited on the basis of their bone mineral density (BMD) and personal history of fragility fracture. The primary statistical analyses will be focused on the comparison of gut microbiota diversity according to BMD (in women with the same fracture status) and according to the fracture status (in women with similar BMD). The investigators will analyze interactions of the gut microbiota diversity, its metabolic activity and other metabolic factors on the one hand, with bone status on the other hand. The investigators will study the association of gut microbiota composition with bone turnover rate, BMD, bone microarchitecture, bone strength estimated by microfinite element analysis (micro-FEA) and with physical performance, muscle mass and strength. The investigators will assess the impact of microRNAs modulating the expression of inflammatory cytokines on the serum levels of these cytokines according to the pattern of gut microbiota diversity and their associations with the characteristics of bone status (e.g. bone microarchitecture). The investigators will analyze the association between serum serotonin, abundance of intestinal bacteria stimulating serotonin synthesis (some Clostridia species) in the colon and the characteristics of bone status.

This study will provide new data concerning the importance of gut microbiota for the fracture risk in older women. The main limitation of this study is its cross-sectional design but this is the first clinical study exploring this subject. It will help to identify the main metabolic pathways underlying the observed associations. These data will stimulate experimental studies to elucidate biological mechanisms underlying these associations. the results will provide indications for future clinical and experimental studies. In the long run, the results will lead up to future studies permitting to develop new biological markers of fracture risk in older women and new anti-osteoporotic medications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bone Loss, Age-related

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

The composition of the intestinal microbiota will be evaluated by the ratio between the amount of pro-inflammatory bacteria (Prevotellaceae, E. coli, Bacteroides vulgatus, Proteus mirabili) and the amount of anti-inflammatory bacteria (Faecalibacterium, Roseburia) in postmenopausal women with comparable bone mineral density, according to their fracture status.

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A. Normal BMD, no fracture

Post-menopausal women with normal bone density (BMD t-score \>-1.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.

Group Type EXPERIMENTAL

bone densitometry

Intervention Type RADIATION

Bone Mineral Density (BMD), body composition, vertebral fractures

High resolution peripheral QCT

Intervention Type RADIATION

High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength

Collection of biological samples

Intervention Type DIAGNOSTIC_TEST

Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition

questionnaires

Intervention Type OTHER

Epidemiologic and nutritional questionnaire and physical activity scale

clinical tests

Intervention Type OTHER

physical performance tests and grip strenght measurement

Group B. Normal BMD, with fracture

Post-menopausal women with normal bone density (BMD T-score \>-1.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.

Group Type EXPERIMENTAL

bone densitometry

Intervention Type RADIATION

Bone Mineral Density (BMD), body composition, vertebral fractures

High resolution peripheral QCT

Intervention Type RADIATION

High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength

Collection of biological samples

Intervention Type DIAGNOSTIC_TEST

Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition

questionnaires

Intervention Type OTHER

Epidemiologic and nutritional questionnaire and physical activity scale

clinical tests

Intervention Type OTHER

physical performance tests and grip strenght measurement

Group C. osteoporotic, no fracture

Post-menopausal women with low bone density (BMD T-score \<-2.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.

Group Type EXPERIMENTAL

bone densitometry

Intervention Type RADIATION

Bone Mineral Density (BMD), body composition, vertebral fractures

High resolution peripheral QCT

Intervention Type RADIATION

High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength

Collection of biological samples

Intervention Type DIAGNOSTIC_TEST

Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition

questionnaires

Intervention Type OTHER

Epidemiologic and nutritional questionnaire and physical activity scale

clinical tests

Intervention Type OTHER

physical performance tests and grip strenght measurement

Group D. osteoporotic, with fracture

Post-menopausal women with low bone density (BMD T-score \<-2.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.

Group Type EXPERIMENTAL

bone densitometry

Intervention Type RADIATION

Bone Mineral Density (BMD), body composition, vertebral fractures

High resolution peripheral QCT

Intervention Type RADIATION

High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength

Collection of biological samples

Intervention Type DIAGNOSTIC_TEST

Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition

questionnaires

Intervention Type OTHER

Epidemiologic and nutritional questionnaire and physical activity scale

clinical tests

Intervention Type OTHER

physical performance tests and grip strenght measurement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bone densitometry

Bone Mineral Density (BMD), body composition, vertebral fractures

Intervention Type RADIATION

High resolution peripheral QCT

High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength

Intervention Type RADIATION

Collection of biological samples

Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition

Intervention Type DIAGNOSTIC_TEST

questionnaires

Epidemiologic and nutritional questionnaire and physical activity scale

Intervention Type OTHER

clinical tests

physical performance tests and grip strenght measurement

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* post-menopausal women
* with a normal Bone Mineral Density (T-score \>-1.5) at the 3 sites (lumbar spine, total hip and femoral neck) or with osteoporosis (T-score ≤ -2.5) at least at one of the 3 sites.

Exclusion Criteria

* Current antibiotherapy or in the last 6 months or repeated antibiotherapy
* Current corticotherapy or stopped for less than 6 months
* Current treatment of osteoporosis or having lasted more than 3 months in the last 5 years
* Current hormonal treatment for menopause
* Current or discontinued drugs that may affect bone metabolism (eg anti-aromatase)
* Known hepatic, cardiac or respiratory insufficiency
* Pathologies that may affect bone metabolism, particularly severe renal insufficiency
* Serious illnesses, particularly disabling and chronic diseases of the gastrointestinal tract
* Diseases characterized by substantial disorders of the gut microbiota (eg severe obesity, BMI\> 40 kg / m2, depression, poorly controlled diabetes)
* Psychiatric pathology hindering understanding
* Difficulty understanding oral French
* Person protected by law, unable to express her consent, subject to a protective measure or deprived of liberty.

Minimum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No